Merck KGaA, a science, and technology company, entered two new strategic drug discovery collaborations aimed at harnessing artificial intelligence (AI)-driven design and discovery capabilities, to further advance research efforts. The partnerships with BenevolentAI and Exscientia are expected to generate several novel clinical development drug candidates with first-in-class and best-in-class potential in key therapeutic areas of oncology, neurology and immunology. Under the terms of the agree...